Download by
Scanning QR Code
No Stock Yet
Pharmaceutical business concept stocks quickly pull up the 4 boards of Jiashitang for 5 days.
The pharmaceutical sector led the rise in the direction of anti-virus.
Gelonghui on December 5, Guizhou lark, Jiashitang, the Yangtze River healthy limit, Shenzhou cells rose by more than 12%, Northeast Pharmaceutical, Hendi Pharmaceutical, Fengyuan Pharmaceutical, and so on are all significantly higher.
Pharmaceutical business concept stocks push up the trading limit of Jiashitang.
On December 2, Gelonghui Drug purchase rose by more than 10%, Jiashitang, Saili Medical limit, gargle civilian, Yixintang, Daga Weikang, Intel Group, Zhejiang Zhenyuan, and so on.
Pharmaceutical commercial stocks pull up collectively, and Jiashitang closes the limit.
On December 1, Gelonghui set off a wave of drug purchases after the optimization of prevention and control measures in many places. Pharmaceutical commercial stocks in the A-share market collectively rose, Jiashitang closed the board in a straight line, gargle civilians, drug Tesco, Dashenlin, Kyushu Tong, and so on. The epidemic prevention and control policy has been optimized in many places throughout the country, and it has been reported that after the epidemic control measures were adjusted in many districts of Guangzhou on November 30, there was a marked increase in the number of customers consulting and purchasing antiviral traditional Chinese medicine. Recently, the sales of this kind of drugs have increased significantly. Xiangxue Pharmaceutical revealed that the company received new orders for 1 million boxes of "Xiangxue antiviral" oral liquid from BABA Pharmacy and Dashenlin yesterday, and the terminal sales of the drug have increased recently than usual.
The pharmaceutical business sector is pulling up and strengthening.
002462.SZ: third quarter net profit fell 14.17% to 77.6357 million yuan
On October 19, 002462.SZ released its third quarter report for 2022, with operating income of 7.574 billion yuan for the reporting period, an increase of 11.57% over the same period last year. Net profit belonging to shareholders of listed companies was 77.6357 million yuan, down 14.17% from the same period last year. Net profit belonging to shareholders of listed companies excluding non-recurring gains and losses was 75.3174 million yuan, down 14.82% from the same period last year; and basic earnings per share was 0.27 yuan.
002462.SZ 's net profit for the first three quarters was 247 million yuan, down 6.96% from the same period last year.
Zhitong Financial APP News, 002462.SZ released a report for the first three quarters of 2022 that the company realized operating income of 20.281 billion yuan, up 4.81% from the same period last year; realized net profit of 247 million yuan belonging to shareholders of listed companies, down 6.96% from the same period last year; and realized net profit of 237 million yuan after deducting non-recurring profits and losses belonging to shareholders of listed companies, down 8.25% from the same period last year. Basic earnings per share is 0.85 yuan per share.
The pharmaceutical commercial plate has been pulled up by different movements.
Kashido (002462.SZ): The ban on 41180.805 million restricted shares will be lifted
Glonghui September 27 丨 Jiashitang (002462.SZ) issued an indicative announcement on the listing and circulation of shares issued to specific targets. The number of shares released this time was 41180.85 million shares, accounting for 14.12% of the company's total share capital, which is RMB common stock issued by the company to specific targets in 2018; the number of shareholders whose share restrictions were lifted this time was 1, China Everbright Group Co., Ltd. (“Everbright Group”); the restricted shares were listed on the Shenzhen Stock Exchange on October 10, 2019, for a limited period of 36 months. 2022/10/10
002462.SZ reported a half-year net profit of 169 million yuan, down 3.24% from a year earlier.
Zhitong Financial APP News, 002462.SZ released a half-annual report for 2022, achieving operating income of 12.706 billion yuan, an increase of 1.15% over the same period last year. The net profit belonging to shareholders of listed companies was 169 million yuan, down 3.24% from the same period last year. The net profit after deducting non-recurring gains and losses belonging to shareholders of listed companies was 162 million yuan, down 4.83% from the same period last year. Basic earnings per share is 0.58 yuan per share. The company gives full play to the subjective initiative of the team, faces up to difficulties, pays close attention to implementation, and firmly ensures the company's four main business boards: pharmaceutical sales, medical devices, pharmaceutical equipment logistics and chain retail.
Loading...
No Stock Yet